Aequus Pharmaceuticals Inc. (AQS.V)
| Previous Close | 0.0650 |
| Open | 0.0600 |
| Bid | 0.0600 x 0 |
| Ask | 0.0700 x 0 |
| Day's Range | 0.0600 - 0.0650 |
| 52 Week Range | 0.0200 - 0.1600 |
| Volume | |
| Avg. Volume | 16,113 |
| Market Cap | 8.621M |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0130 |
| Earnings Date | Jul 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.52 |
- GlobeNewswire
Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 23, 2022 (GLOBE NEWSWIRE) -- Doug Janzen, of 2820 – 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on Tuesday, July 19, 2022, he acquired ownership (the “Acquisition”) of 100,000 common shares (“Common Shares”) in the capital of Aequus Pharmaceuticals Inc. (Address: 2820 – 200 Granville St., Vancouver, BC V6C 1S4) (“Aequus”) through the facilities of the TSX Venture Exchange. Mr. Janzen acquired 99,000 Common Shares at a price of $0.07 per Commo
- GlobeNewswire
Aequus Resumes Trading on TSX Venture Exchange
VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announces that further to our news release dated July 6, 2022, we will resume trading on the TSX Venture exchange tomorrow, July 14, 2022. Doug Janzen noted that “We will be taking steps to lower the risk of this ever happening again. We are excited about the new Scope products announced last week and plan to have other items to add to our product menu in the coming months.” Forw
